Dogs of the Dow Are Rallying While the S&P Slides — Here's Why
Dogs of the Dow Are Rallying While the S&P Slides — Here’s Why…It’s been an odd week on Wall Street: the S&P 500 is on pace for a losing week as chip-sector jitters spread from Asia to U.S. semiconductor names, yet a cluster of unglamorous, high-dividend Dow stocks are having one of their better stretches of the year. The common thread running through several of the winners? They’re all members of the 2026 “Dogs of the Dow.”
What Are the Dogs of the Dow?
The Dogs of the Dow is a decades-old contrarian strategy: at the start of each year, investors identify the ten highest dividend-yielding stocks in the 30-stock Dow Jones Industrial Average and hold them for twelve months, betting that today’s high yield signals a stock that’s out of favor but not out of gas. The 2026 lineup is: IBM, Chevron, Merck, Amgen, Procter & Gamble, Coca-Cola, UnitedHealth Group, Home Depot, Nike, and Johnson & Johnson.
That group skews toward healthcare, staples, and energy — sectors that spent most of the past two years getting ignored while the market chased AI infrastructure names like Nvidia and Oracle. This week, that same unfashionable positioning is working in the Dogs’ favor.
Healthcare Is Doing the Heavy Lifting
The clearest driver is earnings. UnitedHealth Group reported a blowout second quarter on July 16, beating on both revenue and profit and raising its full-year guidance on the back of disciplined medical-cost management. Shares jumped as much as 7.6% intraday, extending a year-to-date gain that was already north of 27% heading into the print. Johnson & Johnson also posted solid Q2 numbers — revenue up 6.6% to $25.3 billion, with management nudging full-year guidance higher — though shares dipped modestly intraday as investors weighed pipeline competition in oncology and immunology.
Beyond single-name earnings, strategists point to a broader rotation: institutional investors are shifting into defensive, cash-generative sectors like managed care and pharma as valuations in AI-adjacent tech start to look stretched. The Health Care Select Sector SPDR Fund has been climbing back above key resistance levels in recent sessions, and managed-care names in particular have seen a pickup in trading volume consistent with that rotation.
Meanwhile, the S&P Is Getting Dragged Down by Chips
The other half of this story is what’s happening outside the Dogs. The S&P 500 and Nasdaq Composite have both been under pressure this week as a semiconductor selloff that started in Asia — SK Hynix and Samsung Electronics both logged sharp swings around SK Hynix’s Nasdaq debut — spilled into U.S. chip names. Applied Materials, KLA Corporation, and other equipment makers have all traded lower on renewed worries about the durability of AI capital spending. That’s a very different environment than the one that lifted Netflix’s Q2 earnings reaction or the record cloud growth in Oracle’s Q4 results just a few weeks ago — this week, growth and AI-linked names are the ones under the most pressure, not the ones setting the pace.
The Dow Jones Industrial Average itself has held up noticeably better than the S&P and Nasdaq through this stretch, in part because it carries less semiconductor weight and more of the defensive, dividend-paying names that make up the Dogs list. That’s echoed in this week’s bank earnings blowout, where financials — another Dow-heavy, value-oriented corner of the market — also posted strong results, in contrast to the chip-driven weakness hitting names like Marvell.
Not Every Dog Is Barking Loudly
It’s worth being precise here: this isn’t a case of all ten Dogs moving in lockstep. UnitedHealth is the standout, and Johnson & Johnson’s fundamentals are solid even if the stock reaction was muted. The rest of the list — Chevron, Merck, Amgen, Procter & Gamble, Coca-Cola, Home Depot, and Nike — are a mixed bag day to day, and the Dogs of the Dow strategy has historically lagged the broader market more often than it’s led it. The setup for 2026 has been unusually favorable so far because the group entered the year cheap relative to the S&P 500, trading at a meaningfully lower multiple of forward earnings, which left more room for a re-rating if sentiment shifted toward value and income.
The Takeaway
This week is a fairly textbook example of sector rotation: money moving out of richly valued, AI-linked growth names and into cheaper, dividend-paying value stocks as questions about semiconductor demand resurface. Whether that rotation has staying power will depend on whether the chip selloff proves temporary or whether AI capex worries deepen — and on whether healthcare’s earnings strength this quarter continues into the back half of the year. For a closer look at any of the individual names above, visit our full Stock Fact Sheets hub.
For informational purposes only. This article does not constitute investment advice.
About the Author
